Unique ID issued by UMIN | UMIN000021630 |
---|---|
Receipt number | R000024947 |
Scientific Title | Anti-VEGF and steroid combination therapy for diabetic macular edema |
Date of disclosure of the study information | 2016/03/27 |
Last modified on | 2018/08/15 20:05:51 |
Anti-VEGF and steroid combination therapy for diabetic macular edema
Combination therapy for DME
Anti-VEGF and steroid combination therapy for diabetic macular edema
Combination therapy for DME
Japan |
diabetic macular edema
Ophthalmology |
Others
NO
To clarify the usefulness of intraviteal steroid injection can reduce number of anti VEGF injection for diabetic macular edema(DME).
Efficacy
The number of anti-VEGF injection.
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Active
2
Treatment
Medicine |
Two months after loading phase treatment of intravitreal ranibizumab injection(IVR), we perform extra injection of IVR.
Two months after loading phase treatment of intravitreal ranibizumab injection(IVR), we perform extra injectionof intravitreal triamcinolone acetonide injection (IVTA).
20 | years-old | <= |
Not applicable |
Male and Female
1)Type I,II diabetes patients over 20 yrs old with IC.
2)Patient with Clinically Significant Macular Edema(CSME)and diffuse macular edema difficult to treat only with laser phitocoagulation(PC).
3)VA disturbances due to DME,not due to diabetic retinopathy.
4)LogMAR BCVA 1.52-1.22
5)Central retinal thickness(by 1 mm of OCT retinal map)over 300 microm.
1)Patients treated PC within 3 months before treatment.
2)Ischemic maculopathy with FA.
3)Vitreal macular traction
4)Proliferative diabetic retinopathy
5)Glaucoma
6)Optic neuropathy
7)Past history of vitreous surgery
8)Phakic eyes
9)Any history of intravitreal injection or subtenon injection.
10)Past history of cataract surgery.
11)Steroid respondar
12)Heart failure, cerebral vascular disease,hematological dissease, tumor.
13)Patients receive general steroid treatment.
14)Hheavy renal failure over stageIII.
15)GradeIII HT
16)HbA1c NGSP over 10%
50
1st name | |
Middle name | |
Last name | Masahiko Sugimoto |
Mie University, school of medicine
Ophthalmology
2-174, Edobashi, Tsu, Mie
0592315027
sugmochi@clin.medic.mie-u.ac.jp
1st name | |
Middle name | |
Last name | Masahiko Sugimoto |
Mie Universivt, School of Medicine
Ophthalmology
2-174, Edobashi, Tsu, Mie
0592315027
sugmochi@clin.medic.mie-u.ac.jp
Department of Ophthalmology, Mie Universivt, School of Medicine
Department of Ophthalmology, Mie Universivt, School of Medicine
Self funding
NO
2016 | Year | 03 | Month | 27 | Day |
Unpublished
Completed
2015 | Year | 02 | Month | 01 | Day |
2015 | Year | 02 | Month | 01 | Day |
2016 | Year | 03 | Month | 27 | Day |
2018 | Year | 08 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024947
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |